Abstracts tagged "remission and rheumatoid arthritis (RA)"

Abstract Number: 1306 • 2013 ACR/ARHP Annual Meeting
Do Sustained Clinical Remission and Sustained Low Disease Activity Equally Predict Functional Status In Early Rheumatoid Arthritis?
Bindee Kuriya¹, Juan Xiong², Gilles Boire³, Boulos Haraoui⁴, Carol A. Hitchon⁵, Janet E. Pope⁶, J. Carter Thorne⁷, Diane Tin⁸, Edward C. Keystone⁹, Cheryl Barnabe¹⁰, Pooneh Akhavan¹¹ and Vivian P. Bykerk¹², ¹Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ²Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ³Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁴Rheumatology, Institut de Rhumatologie de Montréal, Montreal, QC, Canada, ⁵University of Manitoba, Winnipeg, MB, Canada, ⁶Rheumatology, St Joseph Health Centre, London, ON, Canada, ⁷Southlake Regional Health Centre, Newmarket, ON, Canada, ⁸The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ⁹Department of Medicine, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ¹⁰Medicine, Community Health Sciences, University of Calgary, Calgary, AB, Canada, ¹¹Medicine, Early Rheumatoid Arthritis Program, Mount Sinai Hospital and University of Toronto, Toronto, ON, Canada, ¹²Divison of Rheumatology, Hospital for Special Surgery, New York, NY
Background/Purpose: Sustained clinical remission (REM) is the therapeutic goal in rheumatoid arthritis (RA) but low disease activity (LDA) may be acceptable. Little is known…
Abstract Number: 2610 • 2012 ACR/ARHP Annual Meeting
Predictors of Sustained Clinical Remissionin Early Rheumatoid Arthritis – Results From the Canadian Early Arthritis Cohort
Bindee Kuriya¹, Juan Xiong², Gilles Boire³, Boulos Haraoui⁴, Carol A. Hitchon⁵, Janet E. Pope⁶, J. Carter Thorne⁷, Diane Tin⁸, Edward Keystone⁹, Vivian P. Bykerk¹⁰ and CATCH¹¹, ¹Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ²Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ³Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁴Osteoarthritis Research Unit, University of Montreal Hospital Research Centre (CRCHUM), Montreal, QC, Canada, ⁵University of Manitoba, Winnipeg, MB, Canada, ⁶Medicine/Rheumatology, St. Joseph Health Care London, University of Western Ontario, London, ON, Canada, ⁷Southlake Regional Health Centre, Newmarket, ON, Canada, ⁸The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ⁹University of Toronto, Toronto, ON, Canada, ¹⁰Rheumatology, Hospital for Special Surgery, New York, NY, ¹¹Dr. Vivian P. Bykerk, Toronto, ON, Canada
Background/Purpose: Rapid time-to-remission has been associated with sustained remission in established rheumatoid arthritis (RA)1. However, the prevalence and predictive factors of sustained remission in early…
Abstract Number: 400 • 2012 ACR/ARHP Annual Meeting
High Patient Global Assessment Scores Associate with the Residual Disease Activity Unidentified by a 28-Joint Examination in Rheumatoid Arthritis Patients Approaching Clinical Remission
Yasushi Inoue¹, Eiichi Tanaka², Ayako Nakajima³, Eisuke Inoue⁴, Akiko Kobayashi⁴, Daisuke Hoshi¹, Naoki Sugimoto⁴, Kumi Shidara⁴, Yohei Seto⁴, Atsuo Taniguchi⁴, Shigeki Momohara¹ and Hisashi Yamanaka¹, ¹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ²Tokyo Women's Medical University, Tokyo, Japan, ³Rheumatology, Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan, ⁴Institute of Rheumatology, Tokyo Women’s Medical University, Tokyo, Japan
Background/Purpose: Patient global assessment (PtGA) is a component of the new ACR/EULAR remission criteria for rheumatoid arthritis (RA). It has been reported that >50% of…
Abstract Number: 2605 • 2012 ACR/ARHP Annual Meeting
Exploration of Possible Preliminary Descriptions of Remission Based On RAPID3, without Laboratory Tests or Formal Joints Counts but with Careful Joint Examinations, in the Etude Et Suivi Des Polyarthrites Indifférenciées Récentes (ESPOIR) Cohort of Early Rheumatoid Arthritis Patients
Isabel Castrejón¹, Maxime Dougados², Bernard Combe³, Bruno Fautrel⁴ and Theodore Pincus¹, ¹Rheumatology, Rush University Medical Center, Chicago, IL, ²Rheumatology B Department, Paris-Descartes University, APHP, Cochin Hospital, Paris, France, ³Rheumatology, Hopital Lapeyronie, Montpellier, France, ⁴Rheumatology / GRC08-EEMOIS, APHP-Pitie Salpetriere Hospital / UPMC, Paris, France
Background/Purpose: Criteria for remission in rheumatoid arthritis (RA) have been developed according to DAS28 (disease activity score), CDAI (clinical disease activity index), and two recent…
Abstract Number: 404 • 2012 ACR/ARHP Annual Meeting
Remission is a Difficult Target in Clinical Practice When RA Disease Is Established
Till Uhlig¹, Elisabeth Lie², Cecillie Kaufmann³, Erik Rødevand⁴, Knut Mikkelsen⁵, Synnøve Kalstad⁶ and Tore K. Kvien¹, ¹Dept. of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ²Rheumatology, Diakonhjemmet Hospital, Oslo, Norway, ³Rheumatology department, Vestre Viken, Drammen, Norway, ⁴Dept. of Rheumatology, St. Olavs Hospital, Trondheim, Norway, ⁵Lillehammer Hospital for Rheumatic Diseases, Lillehammer, Norway, ⁶Dept. of Rheumatology, University Hospital of Northern Norway, Tromsø, Norway
Background/Purpose: Clinical remission is the treatment target in rheumatoid arthritis (RA) and several composite indices are available for evaluation of remission and low disease activity…
Abstract Number: 2140 • 2012 ACR/ARHP Annual Meeting
A Longitudinal Study of Prognostic Factors in Patients with Early RA Providing Direction for Future Clinical Treatment- Predict Study
Paul Bird¹, David Nicholls², Julien P. de Jager³, Hedley Griffiths⁴, Lynden Roberts⁵, Kathleen Tymms⁶, Jane Zochling⁷, Mark H. Arnold⁸, Geoffrey O. Littlejohn⁹ and OPAL Consortium¹⁰, ¹Combined Rheumatology Practice, Sydney, Australia, ²Coast Joint Care, Maroochydore, Australia, ³Suite 2, Osler House, Southport, Australia, ⁴Barwon Rheumatology Service, Geelong, Australia, ⁵School of Medicine, James Cook University, Townsville, Australia, ⁶Canberra Rheumatology, Canberra, ACT, Australia, ⁷Menzies Research Institute Tasmania, Hobart, Australia, ⁸Orthopaedic Arthritis Spec Ctr, Level 2 The Gallery, Chatswood, Australia, ⁹Rheumatology, Monash Medical Center, Melbourne, Australia, ¹⁰Melbourne, Australia
Background/Purpose: Despite the conspicuous increase in available treatment for rheumatoid arthritis [RA], and the shift to early, more aggressive management, there is a paucity of…
Abstract Number: 405 • 2012 ACR/ARHP Annual Meeting
Frequencies of Boolean and Index Based ACR-EULAR Remissions Differ Slightly Depending On the Method of Patient Global Assessment
Paul Studenic¹, Josef S. Smolen¹ and Daniel Aletaha², ¹Department of Internal Medicine 3, Division of Rheumatology, Medical University Vienna, Vienna, Austria, ²Department of Internal Medicine 3, Division of Rheumatology, Medical University of Vienna, Vienna, Austria
Background/Purpose: Two definitions of remission have been put forward by the ACR and EULAR: a Boolean based, requiring swollen and tender joint counts (SJC, TJC),…
Abstract Number: 2105 • 2012 ACR/ARHP Annual Meeting
Significant Correlation Between ACR/EULAR Remission Criteria and a Simplified Measure Using RAPID3 and Careful Joint Examination without a Formal Joint Count
Martin J. Bergman¹, Isabel Castrejón² and Theodore Pincus², ¹Taylor Hospital, Ridley Park, PA, ²Rheumatology, Rush University Medical Center, Chicago, IL
Background/Purpose: Definitions for the classification of “remission” have been proposed by ACR/EULAR: Boolean and SDAI1 swollen joint can be performed without interfering with usual patient interactions,…
Abstract Number: 131 • 2012 ACR/ARHP Annual Meeting
Subclinical Arthritis Visualised by Positron Emission Tomography and Macrophage Targeting Precedes Clinical Flare in Rheumatoid Arthritis Patients in DAS28 Remission
Y.Y.J. Gent¹, A.E. Voskuyl¹, N. Ahmadi², N. Hoetjes³ and C.J. van der Laken¹, ¹Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ²Radiology, VU University Medical Center, Amsterdam, Netherlands, ³Nuclear Medicine & PET research, VU University Medical Center, Amsterdam, Netherlands
Background/Purpose: Macrophages play an important role in the pathophysiology of Rheumatoid Arthritis (RA). Targeting of macrophages by (R)-[11C]PK11195 positron emission tomography (PET) has previously been successfully…
Abstract Number: 2064 • 2012 ACR/ARHP Annual Meeting
Regular Measure of Disease Activity During the Routine Care of Rheumatoid Arthritis Patients Involves Some Extra Work but Positive Results
Lissiane K. N. Guedes¹, Ana Cristina Medeiros Ribeiro², Karina Rossi Bonfiglioli³, Diogo Domiciano¹, Carolina Reither Vizioli¹, Gilmara Franco da Cunha¹, Andressa Silva Abreu¹, Filipi M. Mello¹, Ana Luiza de Aguiar Foelkel⁴, Celio R. Gonçalves¹ and Ieda Laurindo¹, ¹Rheumatology, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ²Reumatologia, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil, ³Rheumatology Division, Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, ⁴Rheumatology, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil
Background/Purpose: According to treat to target recommendations the use of validated composite measures of disease activity, which include joint assessments, is needed in routine clinical…
Abstract Number: 113 • 2012 ACR/ARHP Annual Meeting
Power Doppler Signal Is Frequently Positive Among Patients with Rheumatoid Arthritis in Clinical Remission and Normal Serum Matrix Metalloproteinase-3 (MMP-3) Levels
Tadashi Okano¹, Tatsuya Koike², Masahiro Tada¹, Kenji Mamoto¹, Yuko Sugioka¹, Atsuko Kamiyama² and Hiroaki Nakamura¹, ¹Orthopedic Surgery, Osaka City University Medical School, Osaka, Japan, ²Rheumatosurgery, Osaka City University Medical School, Osaka, Japan
Background/Purpose: Serum matrix metalloproteinase-3 (MMP-3) is useful bio markers of synovitis associated with rheumatoid arthritis (RA). Ultrasonography (US) has recently become more popular as a…
Abstract Number: 1682 • 2012 ACR/ARHP Annual Meeting
Sustained Clinical Remission (Disease Activity Score 28 <2.6) Protects for Cardiovascular Disease in Rheumatoid Arthritis Patients
Elke.E.A. Arts¹, Jaap Fransen², Alfons A. den Broeder³, Calin Popa¹ and Piet L.C.M. van Riel¹, ¹Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ²Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ³Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands
Background/Purpose: Chronic inflammation appears to be an independent risk factor for CVD in rheumatoid arthritis (RA), but there is no clear difference in CVD risk…
Abstract Number: 78 • 2012 ACR/ARHP Annual Meeting
Factors Influencing On the Discordance Between 2011 ACR/EULAR Criteria and Physician’s Clinical Judgment for Remission in Rheumatoid Arthritis Patients
Yoon-Kyoung Sung¹, Bo Young Yoon², Soo-Kyung Cho¹, Chan-Bum Choi¹, Dae-Hyun Yoo³, Jae-Bum Jun³, Tae-Hwan Kim³, Shin-Seok Lee⁴, Tae-Jong Kim⁵, Jisoo Lee⁶, Jung-Yoon Choe⁷, Sung-Hoon Park⁸, Seung-Jae Hong⁹, Yeon-Ah Lee⁹, Jinseok Kim¹⁰, Eun-Mi Koh¹¹, Hoon-Suk Cha¹¹, Jaejoon Lee¹¹, Won-Tae Chung¹², Sung Won Lee¹², Choong-Ki Lee¹³, Hye-Soon Lee¹⁴, Wan-Hee Yoo¹⁵, Young Mo Kang¹⁶ and Sang-Cheol Bae³, ¹Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ²Inje University Ilsan Paik Hospital, Goyang, South Korea, ³Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea, ⁴Dept of Int Med/Rheumatology, Chonnam National University Medical School, Gwangju, South Korea, ⁵Rheumatology, Chonnam National University Medical School, Gwangju, South Korea, ⁶Internal Medicine, Ewha Womans University Mokdong Hospital, Seoul, South Korea, ⁷Internal Medicine, Catholic University of Daegu School of Medicine, Daegu, South Korea, ⁸Catholic University of Daegu School of Medicine, Daegu, South Korea, ⁹Division of Rheumatology, Department of Internal Medicine, Kyung Hee University, Seoul, South Korea, ¹⁰Division of Rheumatology, Internal Medicine, Jeju National University Hospital, Jeju, Korea, South Korea, ¹¹Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, ¹²Rheumatology, Dong-A University Hospital, Busan, South Korea, ¹³Yeungnam University Hospital, Daegu, South Korea, ¹⁴Department of Rheumatology, Hanyang University Guri Hospital, Guri, South Korea, ¹⁵Rheumatology, Department of Internal Medicine, Chonbuk National University Medical School and Research Institute of Clinical Medicine, Jeonju, South Korea, ¹⁶Department of Internal Medicine (Rheumatology), Kyungpook National University School of Medicine, Daegu, South Korea
Background/Purpose: Remission is a primary end point in the treatment of rheumatoid arthritis (RA). To ensure more uniform reporting of outcome measures, American College of…
Abstract Number: 1594 • 2012 ACR/ARHP Annual Meeting
Clinical and Radiological Outcomes After One Year of Remission Steered Combination Treatment in Patients with Early Rheumatoid and Undifferentiated Arthritis
L. Heimans¹, K.V.C. Wevers-de Boer¹, K. Visser¹, H.K. Ronday², M. van Oosterhout³, J. H. L. M. Van Groenendael⁴, A.J. Peeters⁵, G. Steup-Beekman⁶, G. Collee⁷, P.B.J Sonnaville⁸, B.A. Grillet⁹, Tom Huizinga¹ and C.F. Allaart¹, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Haga Hospital, The Hague, Netherlands, ³Rheumatology, Groene Hart Hospital, Gouda, Netherlands, ⁴Franciscus Hospital, Roosendaal, Netherlands, ⁵Rheumatology, Reinier de Graaf Gasthuis, Delft, Netherlands, ⁶Rheumatology, Bronovo Hospital, Netherlands, ⁷MCH, The Hague, Netherlands, ⁸Admiraal de Ruyter Ziekenhuis, Goes, Netherlands, ⁹Department of Rheumatology, Zorgsaam Hospital, Terneuzen, Netherlands
Background/Purpose: To evaluate the 1 year clinical and radiological outcomes of remission steered therapy in early arthritis patients treated aiming at remission (DAS
Abstract Number: 80 • 2012 ACR/ARHP Annual Meeting
Validation of Remission of Rheumatoid Arthritis by Traditional Disease Activity Score and Provisional Criteria by American College of Rheumatology and European League Against Rheumatism: Patient Reported Outcomes Analyzed From 3 Phase III Golimumab Trials
Chenglong Han¹, Edward Keystone², Roy Fleischmann³, Josef S. Smolen⁴, Paul Emery⁵, Mark C. Genovese⁶, Mittie K. Doyle⁷ and Elizabeth C. Hsia⁷, ¹Outcomes Research, Johnson & Johnson Pharmaceutical Services, LLC, Malvern, PA, ²Rebecca MacDonald Centre for Arthritis and Autoimmune Disease, University of Toronto, Toronto, ON, Canada, ³Southwestern Medical Center at Dallas, University of Texas, Dallas, TX, ⁴Division of Rheumatology, Department of Internal Medicine III,, Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ⁵Medicine, Leeds Musculoskeletal Biomedical Research Unit, Leeds, United Kingdom, ⁶Division of Rheumatology, Stanford University, Palo Alto, CA, ⁷Janssen Research and Development, LLC, Spring House, PA
Background/Purpose: Remission by Boolean-based definition (all scores on the tender joint and swollen joint count, CRP (mg/dL), and patient global assessment ≤1) and by Simplified…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.